Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
vascular disease
Biotech
Vaderis' $152M to fund ph. 3 trial in rare blood vessel disorder
The Basel-based biotech launched the late-stage study to evaluate engasertib in patients with hereditary hemorrhagic telangiectasia.
Marissa Russo
Aug 11, 2026 7:00am
Custom gene editor fixes mutation causing deadly disease in mice
Sep 11, 2025 1:48pm
How a nanomedicine could treat complications of vascular disease
Dec 9, 2021 3:30pm
Abbott builds out endovascular offerings with Walk Vascular buy
Sep 2, 2021 12:18pm
Avicenna's pulmonary-embolism-spotting AI OKed in U.S., EU
Jun 2, 2021 10:15am
AdComm experts split on whether to OK ChemoCentryx's avacopan
May 7, 2021 6:47am
